Cargando…
New targets for the treatment of follicular lymphoma
The last two decades have witnessed striking advances in our understanding of the biological factors underlying the development of Follicular lymphoma (FL). Development of newer treatment approaches have improved the outlook for many individuals with these disorders; however, with these advances com...
Autores principales: | Tageja, Nishant, Padheye, Subhash, Dandawate, Prasad, Al-Katib, Ayad, Mohammad, Ramzi M |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2805680/ https://www.ncbi.nlm.nih.gov/pubmed/20030851 http://dx.doi.org/10.1186/1756-8722-2-50 |
Ejemplares similares
-
Bendamustine: Safety and Efficacy in the Management of Indolent Non-Hodgkins Lymphoma
por: Tageja, Nishant
Publicado: (2011) -
Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-X(L )and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma model
por: Arnold, Alan A, et al.
Publicado: (2008) -
An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals
por: Mohammad, Ramzi M, et al.
Publicado: (2009) -
Targeting CD19 in B-cell lymphoma: emerging role of SAR3419
por: Raufi, Ali, et al.
Publicado: (2013) -
Targeted Treatment of Follicular Lymphoma
por: Nath, Karthik, et al.
Publicado: (2021)